appointment of non-executive director, page-26

Monash has shown its commitment, and so in return management, over the past year.

The conditions were obviously not met up until now to channel the funds, for reasons many speculated earlier about.


When bringing a new technology to market with such far reaching commercial consequences, not only for the company in question but for the entire state, it does not surprise that many mouths will be fed before the developments moves along.

That is common business practice and actually indicators for investors to look out for before committing to invest.


The very thing you criticise as being unfair to holders is the most convincing part of our story in the moment.
Insiders are fed and are looked after.

My personal view is to let this pass, run its course, you can not do anything about it anyway and lean back and wait until the broader ripples will also, in my opinion, hit your portfolio.

That is the nature of development in any industry and something one has to respect when investing.



I understand your frustration in regards to the dilution but you voice your anger at a time when it all comes to an end and, most likely, will trigger announcements regarding Monash.
By now, it can be hardly a secret that Monash has waited until the commercialisation of Coldry is derisked in its way forward.
Why else did management and Monash continue to express their commitment to each other?


In my opinion, the time we have received an offer letter from the DPI would mark the funding arrangement with Monash.